News >

Encouraging Data Advance Research in Relapsed/Refractory Myeloma

Ellie Leick
Published: Thursday, Sep 05, 2019

Amrita Krishnan, MD

Amrita Krishnan, MD

Therapeutic options for relapsed/refractory multiple myeloma are quickly evolving, following an explosion of data presented over the last several months, explained Amrita Krishnan, MD.

For example, results of the phase III COLUMBA trial found that daratumumab (Darzalex) can be given subcutaneously rather than intravenously without comprising efficacy in patients with relapsed/refractory multiple myeloma.1 Based on these data, a supplemental biologics license application was submitted to the FDA in July 2019 for the new subcutaneous formulation as a treatment for patients with multiple myeloma.

Data have also read out with another CD38-directed monoclonal antibody. In the ICARIA-MM trial, which looked at isatuximab plus pomalidomide (Pomalyst)/dexamethasone versus pomalidomide/dexamethasone alone, findings showed a greater than 40% reduction in the risk of disease progression or death in the isatuximab arm.2 In July 2019, the FDA accepted a biologics license application for isatuximab for the treatment of patients with relapsed/refractory disease.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x